Saturday’s ASCO plenary delivered three datasets that will change how cancer is treated. Revolution Medicines confirmed everything the topline promised and added the missing piece: PFS. At 7.2 months versus 3.6 months (HR 0.49, p<0.0001), daraxonrasib doubled progression-free survival in second-line pancreatic cancer, matching the OS doubling (13.2 vs. 6.7 months, HR 0.40, p<0.0001) reported in April. The results held across both the RAS G12 population and the full intent-to-treat population. The data were published simultaneously in The New England Journal of Medicine. The FDA granted expanded access. Revolution intends to file under the CNPV program. Meanwhile, Akeso’s ivonescimab made history as the first Chinese drug selected for the ASCO plenary in the society’s 61-year history, demonstrating a statistically significant overall survival benefit (HR 0.66) over PD-1 plus chemotherapy in squamous NSCLC. And J&J’s PROTEUS data showed that adding Erleada before and after prostate surgery reduced metastasis or death in a 2,000-patient study, addressing what J&J called a “125-year treatment gap.” Three plenary sessions. Three treatment paradigms changed.
Your ASCO field guide is live. Searchable, filterable, catalyst-aware. Bookmark it → biomednexus.com/asco-2026
Revolution Medicines Confirms Practice-Changing Data in Pancreatic Cancer
What Happened: Brian Wolpin, MD, MPH (Dana-Farber Cancer Institute) presented the primary and final analysis of the Phase 3 RASolute 302 trial in a plenary session at ASCO on Saturday May 31. The data were published simultaneously in The New England Journal of Medicine.
The Full Dataset
The trial enrolled 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Data cutoff was February 10, 2026, with a median follow-up of 8.5 months.
Intent-to-Treat Population (daraxonrasib n=248, chemotherapy n=252):
Median overall survival: 13.2 months versus 6.7 months. HR 0.40 (95% CI: 0.30 to 0.53; p<0.0001). A 60% reduction in the risk of death.
Median progression-free survival: 7.2 months versus 3.6 months. HR 0.49 (95% CI: 0.38 to 0.64; p<0.0001). A 51% reduction in the risk of progression or death.
RAS G12 Population (daraxonrasib n=228, chemotherapy n=231):
Overall survival: HR 0.40. 60% reduction in risk of death. Consistent with the ITT population.
Median PFS: 7.3 months versus 3.5 months. HR 0.45 (95% CI: 0.34 to 0.59; p<0.0001). A 55% reduction in risk of progression or death.
Safety was generally well tolerated with a manageable profile and no new safety signals.
Why the PFS Data Complete the Picture
The PFS result was the missing piece from the April topline readout. Overall survival is the gold standard endpoint in oncology, and the OS data alone would have been sufficient to establish daraxonrasib as a transformative therapy. But PFS provides the complementary evidence that the drug delays disease progression—not just that patients live longer, but that their cancers take longer to grow.
A drug that doubles both PFS and OS in the same trial provides the most complete evidence package any regulatory submission can offer. The consistency between the two endpoints eliminates the possibility that the survival benefit is driven by post-progression effects or imbalances in subsequent therapies. Daraxonrasib is delaying progression and extending life by comparable magnitudes.
The ITT Consistency Is the Label Story
The consistency between the RAS G12 population and the full ITT population is strategically significant for the label. The ITT population includes patients without identified RAS mutations. If the drug only worked in RAS G12 patients, the FDA would likely restrict the label to that biomarker-defined population. The ITT results matching the RAS G12 results supports a broad label that does not require biomarker selection—any patient with previously treated metastatic pancreatic cancer could be eligible.
A broad label dramatically expands the addressable population and simplifies the prescribing workflow for oncologists, who would not need to order a specific biomarker test before prescribing. This is both a clinical advantage (more patients benefit) and a commercial advantage (larger market, fewer prescribing barriers).
The NEJM Publication and Expanded Access
The simultaneous NEJM publication is the gold standard for pivotal oncology data. It is rare for ASCO presentations to receive simultaneous publication in the NEJM, and it signals that the editors viewed the data as practice-changing at the highest level of scientific evidence.
The FDA’s decision to grant expanded access to daraxonrasib for patients with previously treated metastatic PDAC means patients can start receiving the drug before formal approval. This is the strongest possible regulatory signal short of approval itself. It indicates the FDA views the benefit-risk profile as favorable enough to allow access outside of clinical trials while the formal review process proceeds. For pancreatic cancer patients—who face a disease with a five-year survival rate below 15% and have had essentially no effective second-line treatment options—expanded access is not an abstraction. It is immediate access to a drug that doubled their survival in a Phase 3 trial.
Revolution intends to submit an NDA under the CNPV program and to submit data to other global regulatory authorities. Truist projected a Q3 2026 approval. If CNPV review mirrors the 50-day Foundayo precedent, an August or September approval is in range. The combination of NEJM publication, expanded access, and CNPV filing creates the fastest path from Phase 3 readout to market of any oncology drug in recent memory.
Our Pro brief includes the complete dataset analysis, what the ITT/RAS G12 consistency means for label scope, the CNPV filing timeline model, and the expanded access uptake implications. [Details below.]
Ivonescimab Makes History as First Chinese Drug in ASCO Plenary
What Happened: Professor Shun Lu (Shanghai Chest Hospital) presented overall survival data from the Phase 3 HARMONi-6 trial showing ivonescimab (PD-1/VEGF bispecific antibody) plus chemotherapy achieved a statistically significant and clinically meaningful OS improvement over tislelizumab (PD-1) plus chemotherapy in first-line advanced squamous NSCLC. The OS hazard ratio was 0.66—a 34% reduction in the risk of death.
Why This Is Historic
This is the first time a China-originated investigational oncology drug has been selected for the ASCO plenary session in the society’s 61-year history. Akeso CEO Dr. Yu Xia said ivonescimab has “successfully challenged PD-1 plus chemotherapy, achieving both clinically meaningful and statistically significant improvements in overall survival and progression-free survival.”
The PD-1/VEGF bispecific mechanism—simultaneously blocking the immune checkpoint pathway and the angiogenesis pathway—has now demonstrated what many in the field hoped but few expected: an overall survival benefit over the current standard of care. PFS improvements without OS benefit have been a recurring disappointment in immuno-oncology. Ivonescimab converting a PFS advantage into a survival advantage validates the bispecific approach as a genuine advance rather than an incremental improvement.
The U.S. Path Is Complicated but Not Impossible
Summit Therapeutics holds U.S. rights to ivonescimab. The path from ASCO plenary to U.S. FDA approval involves several challenges. HARMONi-6 enrolled exclusively Chinese patients, and the FDA will evaluate whether results are generalizable to a U.S. population with different genetic backgrounds, treatment patterns, and comorbidity profiles. The control arm used tislelizumab, a PD-1 inhibitor that is not widely used in the United States—American oncologists and the FDA will want to see ivonescimab positioned against Keytruda, the established U.S. standard of care.
Whether a U.S. confirmatory trial is required or whether the Chinese data are sufficient for an FDA filing will determine the timeline. If the FDA accepts the HARMONi-6 data as the basis for accelerated approval, the path could be relatively fast. If a U.S. confirmatory trial is required, the timeline extends by years. A separate Akeso study, HARMONi-02, previously showed ivonescimab beat Keytruda in PFS in a different NSCLC population. If HARMONi-02 OS data are positive, they would strengthen the case for the bispecific mechanism and potentially support a U.S. regulatory strategy that combines data from multiple studies.
The data are compelling. The regulatory path is uncertain. The commercial implications—challenging Merck’s Keytruda franchise in the world’s largest immuno-oncology market—are enormous if the regulatory path clears.
J&J’s Erleada Shifts a 125-Year Prostate Cancer Paradigm
What Happened: J&J presented Phase 3 PROTEUS results showing Erleada (apalutamide) given before and after surgery significantly reduced the risk of metastasis or death versus hormone therapy alone in patients with high-risk localized or locally advanced prostate cancer. The 2,000-patient study opened the plenary session.
What Changed
J&J’s U.S. president of oncology for solid tumors, Biljana Naumovic, told Fierce Pharma that the prostatectomy treatment paradigm has been essentially unchanged “since the prostatectomy was introduced 125 years ago in 1904.” J&J oncology VP Mark Wildgust described the perioperative setting as “one chance for curing this patient.”
Currently, patients with high-risk localized prostate cancer receive surgery plus hormone therapy (androgen deprivation therapy). No additional systemic therapy has been standard of care in this perioperative setting. PROTEUS showed that adding apalutamide—a next-generation androgen receptor inhibitor—to the perioperative regimen significantly reduced the risk of the cancer coming back as metastatic disease.
Why Perioperative Matters
Moving into the perioperative setting follows the same trajectory that has defined oncology in 2026: treatments moving earlier in the disease course where the intent is curative. Enhertu in early breast cancer. Datroway in first-line TNBC. Now Erleada in perioperative prostate cancer. Each expansion moves a therapy from the advanced/metastatic setting—where the goal is extending life—to the early/curative setting—where the goal is eliminating the disease entirely.
The perioperative concept is powerful because it addresses the window of maximum therapeutic leverage. Surgery removes the visible tumor. But microscopic disease may remain. Adding systemic therapy before surgery (neoadjuvant, to shrink the tumor and treat micrometastases) and after surgery (adjuvant, to eliminate any remaining cancer cells) gives patients the best chance of cure. PROTEUS demonstrated that adding apalutamide to this perioperative window produced a meaningful reduction in the risk of the cancer returning as metastatic disease—the outcome that patients and physicians fear most after curative-intent surgery.
Prostate cancer is the most common cancer in men. The number of radical prostatectomies performed annually is substantial. Adding a perioperative indication expands Erleada’s addressable population significantly beyond the advanced and metastatic settings where it is currently approved, representing meaningful incremental revenue for J&J’s oncology franchise. J&J will seek FDA approval for the new indication based on the PROTEUS data.
Strategic Themes
1. Revolution’s Data Are as Strong as Oncology Data Get
OS HR 0.40. PFS HR 0.49. Consistent across ITT and biomarker-defined populations. Simultaneously published in the NEJM. Expanded access granted by the FDA. CNPV filing planned. This is the complete package. Daraxonrasib did not just meet the bar for approval—it exceeded it on every dimension. The drug doubled both PFS and OS in a disease that has resisted meaningful therapeutic progress for decades. For pancreatic cancer patients, oncologists, and the industry, the RASolute 302 data represent the clearest practice-changing result in GI oncology in years.
2. A Chinese Bispecific Just Beat PD-1 on Overall Survival—and the Global Implications Are Enormous
Ivonescimab’s OS HR of 0.66 against PD-1 plus chemo is a result that will reverberate across the immuno-oncology landscape. The dual PD-1/VEGF mechanism has demonstrated what single-agent PD-1 inhibitors cannot achieve alone. If the data translate to global populations and the regulatory path clears, ivonescimab could become the first Chinese-developed drug to challenge the Keytruda standard of care on survival in the world’s largest IO market. The ASCO plenary selection—the first Chinese drug in 61 years—is a statement about the quality of Chinese clinical research that the global oncology community cannot ignore.
3. The Perioperative Movement in Oncology Is Accelerating
Erleada in perioperative prostate cancer. Enhertu in early breast cancer. Datroway in first-line TNBC. The pattern of 2026 is treatments moving earlier in the disease course, where the intent shifts from palliation to cure. Each perioperative or early-stage approval expands the addressable patient population by multiples compared to the late-stage setting. J&J’s description of PROTEUS as addressing a 125-year treatment gap underscores how long this gap has existed and how significant the clinical and commercial impact of filling it could be.
4. The CNPV Filing Will Test Whether the Program Survives the Leadership Transition
Revolution plans to file under CNPV. The program approved Foundayo in 50 days. But Commissioner Makary, who created the program, is gone. CDER has a new acting director with limited tenure. The Revolution filing will be the first major CNPV submission since the leadership transition. Whether it receives the same expedited review that characterized the program under Makary—or slows to a more conventional timeline measured in months rather than weeks—will determine whether the CNPV is an institutional capability that persists beyond any single commissioner or whether it was a personal initiative that departed with the leader who championed it. The answer matters not just for Revolution but for every company that has built its regulatory strategy around the assumption that accelerated review programs will continue to function during leadership transitions.
Frequently Asked Questions
What were Revolution’s full Phase 3 results?
In 500 patients with previously treated metastatic pancreatic cancer: median OS 13.2 months versus 6.7 months (HR 0.40, p<0.0001). Median PFS 7.2 months versus 3.6 months (HR 0.49, p<0.0001). Results consistent across ITT and RAS G12 populations. Published simultaneously in the NEJM. FDA granted expanded access. CNPV filing planned.
What was the ivonescimab result?
OS HR 0.66 (34% reduction in death risk) for ivonescimab plus chemo versus PD-1 plus chemo in first-line squamous NSCLC. First Chinese drug in the ASCO plenary in 61 years. Summit Therapeutics holds U.S. rights. The U.S. regulatory path involves challenges including a Chinese-only trial and a non-U.S.-standard control arm.
What did the PROTEUS prostate data show?
Erleada before and after surgery significantly reduced the risk of metastasis or death versus hormone therapy alone in 2,000 patients with high-risk localized prostate cancer. J&J called the perioperative setting “one chance for curing this patient.” The treatment paradigm for prostatectomy has been unchanged for 125 years.
What is expanded access?
The FDA’s decision to allow patients to receive daraxonrasib before formal approval. Patients with previously treated metastatic pancreatic cancer can now access the drug outside of clinical trials. This is the strongest regulatory signal short of approval.
When could daraxonrasib be approved?
Truist projects Q3 2026 under the CNPV program. If CNPV review mirrors the 50-day Foundayo precedent, an August or September approval is in range. Revolution plans to file imminently.
What does the NEJM publication mean?
Simultaneous publication in the New England Journal of Medicine is the highest level of scientific endorsement for clinical data. It signals the editors viewed the RASolute 302 results as practice-changing. It is rare for ASCO presentations to receive simultaneous NEJM publication.
Can ivonescimab challenge Keytruda in the U.S.?
The data are compelling (OS HR 0.66). The path is uncertain. The trial enrolled only Chinese patients with a non-U.S.-standard control arm. A U.S. confirmatory trial may be required. Summit Therapeutics holds U.S. rights but would need to build commercial infrastructure to compete against Merck’s Keytruda franchise.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
RASolute 302: The Complete Dataset. We analyze every dimension of the full Phase 3 data—PFS confirmation, ITT/RAS G12 consistency for label scope, NEJM publication significance, expanded access implications—and model the CNPV filing timeline from submission to projected approval.
Ivonescimab: The U.S. Regulatory Path. We assess whether Chinese-only data can support a U.S. filing, what a confirmatory trial would add to the timeline, how Summit Therapeutics’ commercial capabilities compare to what is needed to compete with Keytruda, and what positive HARMONi-02 OS data would mean for the U.S. strategy.
PROTEUS: The Perioperative Franchise Expansion. We model how adding a curative-intent prostate cancer indication expands Erleada’s addressable population and incremental revenue, and assess how the perioperative movement across oncology creates a new growth vector for established franchises.
Plus: ASCO Day 3 abstract highlights, Revolution expanded access uptake monitoring, CNPV program continuity assessment, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
